vs
NATURES SUNSHINE PRODUCTS INC（NATR）とPriority Technology Holdings, Inc.（PRTH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Priority Technology Holdings, Inc.の直近四半期売上が大きい（$247.1M vs $123.8M、NATURES SUNSHINE PRODUCTS INCの約2.0倍）。Priority Technology Holdings, Inc.の純利益率が高く（3.6% vs 3.3%、差は0.3%）。Priority Technology Holdings, Inc.の前年同期比売上増加率が高い（8.8% vs 4.7%）。Priority Technology Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$30.9M vs $7.6M）。過去8四半期でPriority Technology Holdings, Inc.の売上複合成長率が高い（9.6% vs 5.6%）
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
Priority Technology Holdings, Inc.は情報技術分野に注力する企業で、コンピューターや通信システムをはじめとする情報関連機器を軸に、情報の作成、処理、保存、検索、伝送といった情報技術関連の応用サービスを手がけ、コンピューターサイエンスと工学技術を基盤に事業を展開しています。
NATR vs PRTH — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $123.8M | $247.1M |
| 純利益 | $4.1M | $8.9M |
| 粗利率 | 72.5% | — |
| 営業利益率 | 4.3% | 13.6% |
| 純利益率 | 3.3% | 3.6% |
| 売上前年比 | 4.7% | 8.8% |
| 純利益前年比 | 1379.4% | 23.9% |
| EPS（希薄化後） | $0.23 | $0.10 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $123.8M | $247.1M | ||
| Q3 25 | $128.3M | $241.4M | ||
| Q2 25 | $114.8M | $239.8M | ||
| Q1 25 | $113.2M | $224.6M | ||
| Q4 24 | $118.2M | $227.1M | ||
| Q3 24 | $114.6M | $227.0M | ||
| Q2 24 | $110.6M | $219.9M | ||
| Q1 24 | $111.0M | $205.7M |
| Q4 25 | $4.1M | $8.9M | ||
| Q3 25 | $5.3M | $27.6M | ||
| Q2 25 | $5.3M | $10.9M | ||
| Q1 25 | $4.7M | $8.3M | ||
| Q4 24 | $-321.0K | $7.2M | ||
| Q3 24 | $4.3M | $10.6M | ||
| Q2 24 | $1.3M | $994.0K | ||
| Q1 24 | $2.3M | $5.2M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | 13.6% | ||
| Q3 25 | 7.0% | 15.6% | ||
| Q2 25 | 3.7% | 15.6% | ||
| Q1 25 | 5.4% | 14.5% | ||
| Q4 24 | 3.8% | 15.0% | ||
| Q3 24 | 4.6% | 16.8% | ||
| Q2 24 | 5.1% | 15.1% | ||
| Q1 24 | 4.2% | 13.6% |
| Q4 25 | 3.3% | 3.6% | ||
| Q3 25 | 4.2% | 11.4% | ||
| Q2 25 | 4.6% | 4.5% | ||
| Q1 25 | 4.2% | 3.7% | ||
| Q4 24 | -0.3% | 3.2% | ||
| Q3 24 | 3.8% | 4.7% | ||
| Q2 24 | 1.2% | 0.5% | ||
| Q1 24 | 2.1% | 2.5% |
| Q4 25 | $0.23 | $0.10 | ||
| Q3 25 | $0.30 | $0.34 | ||
| Q2 25 | $0.28 | $0.14 | ||
| Q1 25 | $0.25 | $0.10 | ||
| Q4 24 | $-0.02 | $-0.05 | ||
| Q3 24 | $0.23 | $0.07 | ||
| Q2 24 | $0.07 | $-0.23 | ||
| Q1 24 | $0.12 | $-0.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $93.9M | $77.2M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $161.6M | $-100.4M |
| 総資産 | $261.1M | $2.4B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $93.9M | $77.2M | ||
| Q3 25 | $95.6M | $57.0M | ||
| Q2 25 | $81.3M | $50.6M | ||
| Q1 25 | $86.5M | $47.6M | ||
| Q4 24 | $84.7M | $58.6M | ||
| Q3 24 | $78.7M | $41.1M | ||
| Q2 24 | $68.7M | $34.6M | ||
| Q1 24 | $77.8M | $34.3M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $997.5M | ||
| Q2 25 | — | $917.0M | ||
| Q1 25 | — | $918.9M | ||
| Q4 24 | — | $920.9M | ||
| Q3 24 | — | $808.1M | ||
| Q2 24 | — | $809.0M | ||
| Q1 24 | $2.1M | $631.4M |
| Q4 25 | $161.6M | $-100.4M | ||
| Q3 25 | $166.7M | $-110.3M | ||
| Q2 25 | $163.7M | $-146.1M | ||
| Q1 25 | $167.1M | $-158.3M | ||
| Q4 24 | $161.0M | $-166.8M | ||
| Q3 24 | $162.6M | $-165.8M | ||
| Q2 24 | $156.4M | $-172.1M | ||
| Q1 24 | $159.7M | $-159.9M |
| Q4 25 | $261.1M | $2.4B | ||
| Q3 25 | $264.8M | $2.2B | ||
| Q2 25 | $254.9M | $2.0B | ||
| Q1 25 | $252.7M | $1.9B | ||
| Q4 24 | $240.9M | $1.8B | ||
| Q3 24 | $245.3M | $1.8B | ||
| Q2 24 | $235.8M | $1.7B | ||
| Q1 24 | $247.3M | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $9.9M | $36.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $7.6M | $30.9M |
| FCFマージンFCF / 売上 | 6.1% | 12.5% |
| 設備投資強度設備投資 / 売上 | 1.9% | 2.4% |
| キャッシュ転換率営業CF / 純利益 | 2.41× | 4.12× |
| 直近12ヶ月FCF直近4四半期 | $28.8M | $75.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $9.9M | $36.8M | ||
| Q3 25 | $18.5M | $36.1M | ||
| Q2 25 | $4.3M | $17.1M | ||
| Q1 25 | $2.6M | $10.0M | ||
| Q4 24 | $12.2M | $23.8M | ||
| Q3 24 | $9.6M | $19.8M | ||
| Q2 24 | $1.3M | $28.7M | ||
| Q1 24 | $2.2M | $13.3M |
| Q4 25 | $7.6M | $30.9M | ||
| Q3 25 | $16.8M | $30.1M | ||
| Q2 25 | $3.0M | $9.2M | ||
| Q1 25 | $1.5M | $4.9M | ||
| Q4 24 | $10.0M | $19.1M | ||
| Q3 24 | $7.9M | $14.5M | ||
| Q2 24 | $-2.0M | $23.6M | ||
| Q1 24 | $-1.5M | $6.7M |
| Q4 25 | 6.1% | 12.5% | ||
| Q3 25 | 13.1% | 12.5% | ||
| Q2 25 | 2.6% | 3.8% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 8.5% | 8.4% | ||
| Q3 24 | 6.9% | 6.4% | ||
| Q2 24 | -1.9% | 10.7% | ||
| Q1 24 | -1.4% | 3.3% |
| Q4 25 | 1.9% | 2.4% | ||
| Q3 25 | 1.3% | 2.5% | ||
| Q2 25 | 1.2% | 3.3% | ||
| Q1 25 | 1.0% | 2.3% | ||
| Q4 24 | 1.9% | 2.0% | ||
| Q3 24 | 1.5% | 2.3% | ||
| Q2 24 | 3.0% | 2.3% | ||
| Q1 24 | 3.3% | 3.2% |
| Q4 25 | 2.41× | 4.12× | ||
| Q3 25 | 3.46× | 1.31× | ||
| Q2 25 | 0.81× | 1.57× | ||
| Q1 25 | 0.55× | 1.20× | ||
| Q4 24 | — | 3.29× | ||
| Q3 24 | 2.21× | 1.87× | ||
| Q2 24 | 0.97× | 28.87× | ||
| Q1 24 | 0.94× | 2.56× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
PRTH
セグメントデータなし
